American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (986)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (940)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1255)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3997)
  2. Hematologic Malignancies, Division of (3800)
  3. Center for Hematologic Malignancies (3677)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1341)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (311)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (62)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5172)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ABBV-383 plus daratumumab-dexamethasone in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study
    Meeting Abstract

    Rodriguez, C.; Mielnik, M.; Kazandjian, D.; Janowski, W.; Low, M. S. Y.; Pianko, M.; Yuda, J.; Van Der Weyden, C.; Anderson, L. D. Jr; Banerjee, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Levy, M. Y.; Koller, P. B.; Sasaki, K.; Tantravahi, S. K.; Andorsky, D.; Bremer, C. T.; Zeidner, J. F.; Luskin, M. R.; Munker, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes
    Meeting Abstract

    Salles, G.; Morschhauser, F.; Sehn, L. H.; Herrera, A. F.; Friedberg, J. W.; Trněný, M.; Lenz, G.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly DREAMM-9 interim
    Meeting Abstract

    Usmani, S. Z.; Mielnik, M.; Garg, M.; Sandhu, I.; Abdallah, A. O.; Koh, Y.; Oriol, A.; Quach, H.; Weisel, K. C.; Alonso, A. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDAC™ degrader, in patients with non-Hodgkin's lymphoma
    Meeting Abstract

    Horwitz, S.; Jain, S.; Soumerai, J. D.; Tees, M. T.; Stuver, R.; Ali, A.; Leahy, L.; Lobbardi, R.; Chu, R.; Hurh, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Development of a novel prognostic score for relapsed/refractory mature T-cell and NK-cell lymphomas (PIRT): Results from a global peripheral T-cell lymphoma (PETAL) Consortium
    Meeting Abstract

    Koh, M. J.; Han, J. X.; Boussi, L.; Sorial, M. N.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab in children, adolescents, and young adults with low-risk classic Hodgkin lymphoma (cHL) and slow early response to front-line chemotherapy: Updated results from the phase 2 KEYNOTE-667 study
    Meeting Abstract

    Roth, L. G.; Toledo, M. M.; Keller, F. G.; Hoppe, B.; Forlenza, C. J.; Castellino, S. M.; Catalan, M. A.; Krystal, J.; Lamble, A.; Luisi, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Integrating genomic & transcriptomic features for noninvasive detection, characterization, and monitoring of T-cell lymphomas
    Meeting Abstract

    Sugio, T.; Nesselbush, M.; Shukla, N.; Garofalo, A.; Mutter, J. A.; Esfahani, M. S.; Alig, S. K.; Shi, S.; Noordenbos, T.; Hamilton, M. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2024)

    Fulltext@MSK | Save